Transcatheter Closure of Patent Foramen Ovale: Randomized Trial Update

Angelos Arfaras-Melainis, Leonidas Palaiodimos, Mohammad K. Mojadidi

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


A patent foramen ovale (PFO) is found in about one-quarter of all adults, but the prevalence increases to approximately half of those with a history of a so-called cryptogenic stroke. The true efficacy of PFO closure for prevention of recurrent paradoxical embolism has been debated for years, as the early 3 randomized trials did not show a statistically significant benefit of PFO closure over standard-of-care medical therapy. However, 3 recent randomized trials along with the long-term follow-up data from the largest early trial demonstrated superiority of device closure for secondary stroke prevention.

Original languageEnglish (US)
Pages (from-to)341-356
Number of pages16
JournalInterventional Cardiology Clinics
Issue number4
StatePublished - Oct 2019


  • Cryptogenic stroke
  • ESUS
  • Embolic stroke of undetermined source
  • PFO
  • PFO closure
  • Stroke prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Transcatheter Closure of Patent Foramen Ovale: Randomized Trial Update'. Together they form a unique fingerprint.

Cite this